[go: up one dir, main page]

DE60020613D1 - (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen - Google Patents

(S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen

Info

Publication number
DE60020613D1
DE60020613D1 DE60020613T DE60020613T DE60020613D1 DE 60020613 D1 DE60020613 D1 DE 60020613D1 DE 60020613 T DE60020613 T DE 60020613T DE 60020613 T DE60020613 T DE 60020613T DE 60020613 D1 DE60020613 D1 DE 60020613D1
Authority
DE
Germany
Prior art keywords
reboxetine
fibromyalgia
treatment
somatoform disorders
somatoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020613T
Other languages
English (en)
Other versions
DE60020613T2 (de
Inventor
Saeeduddin Ahmed
Lars Birgerson
Pasquale Cetera
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Erik H F Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60020613(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Application granted granted Critical
Publication of DE60020613D1 publication Critical patent/DE60020613D1/de
Publication of DE60020613T2 publication Critical patent/DE60020613T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60020613T 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen Expired - Lifetime DE60020613T2 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US141968P 1999-07-01
US14413199P 1999-07-16 1999-07-16
US144131P 1999-07-16
US15825699P 1999-10-06 1999-10-06
US158256P 1999-10-06
US17038199P 1999-12-13 1999-12-13
US170381P 1999-12-13

Publications (2)

Publication Number Publication Date
DE60020613D1 true DE60020613D1 (de) 2005-07-07
DE60020613T2 DE60020613T2 (de) 2006-03-16

Family

ID=27495506

Family Applications (9)

Application Number Title Priority Date Filing Date
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien

Family Applications Before (6)

Application Number Title Priority Date Filing Date
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien

Country Status (30)

Country Link
US (18) US6465458B1 (de)
EP (3) EP2090312A1 (de)
JP (3) JP2003503450A (de)
KR (5) KR100704319B1 (de)
CN (5) CN1289090C (de)
AR (1) AR035158A1 (de)
AT (9) ATE304358T1 (de)
AU (2) AU771258B2 (de)
BR (1) BR0012136A (de)
CA (2) CA2643231A1 (de)
CL (3) CL2008002866A1 (de)
CO (1) CO5190662A1 (de)
CZ (1) CZ299847B6 (de)
DE (9) DE60026704T2 (de)
DK (4) DK1196172T3 (de)
EA (6) EA011094B1 (de)
ES (9) ES2258251T3 (de)
GE (1) GEP20094798B (de)
HU (1) HUP0201623A3 (de)
IL (3) IL147246A0 (de)
MX (1) MXPA02000562A (de)
MY (1) MY137348A (de)
NO (4) NO20016406L (de)
NZ (2) NZ515885A (de)
PE (1) PE20010684A1 (de)
PL (1) PL196996B1 (de)
PT (5) PT1459751E (de)
SK (5) SK286104B6 (de)
TW (9) TW200914027A (de)
WO (1) WO2001001973A2 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090312A1 (de) * 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) Reboxetine zur Behandlung von Aufmerksamkeitsstörungen
JP4249415B2 (ja) * 1999-12-01 2009-04-02 ユセベ，ソシエテ アノニム Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
ATE312608T1 (de) * 2000-04-21 2005-12-15 Pharmacia & Upjohn Co Llc Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
JP2004502651A (ja) * 2000-04-21 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 線維筋痛症および慢性疲労症候群の治療
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
JP2004529073A (ja) * 2000-11-15 2004-09-24 イーライ・リリー・アンド・カンパニー 不安障害の治療
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
JP4205577B2 (ja) * 2001-06-19 2009-01-07 ミュラー，ノルベルト 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
DE60223718T2 (de) * 2001-12-11 2008-10-30 Eli Lilly And Co., Indianapolis Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
JP2005522445A (ja) * 2002-02-12 2005-07-28 サイプレス バイオサイエンス， インコーポレイテッド 注意欠陥過活動性障害（ａｄ／ｈｄ）の処置方法
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
EP2301537A1 (de) 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
US7459464B2 (en) * 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
RU2286341C2 (ru) * 2002-06-17 2006-10-27 Фармация Италия С.П.А. Фармацевтические соли ребоксетина
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
ATE327982T1 (de) * 2002-08-23 2006-06-15 Lilly Co Eli Benzylmorpholinderivate
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US20040106681A1 (en) * 2002-10-03 2004-06-03 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
MXPA05007379A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
CN100353946C (zh) * 2003-01-13 2007-12-12 戴诺吉药品有限公司 治疗功能性肠病的方法
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (de) * 2003-08-27 2006-05-31 Eli Lilly And Company Behandlung von pervasiven entwicklungsstörungen mit norepinephrin-wiederaufnahme-hemmern
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
ATE423772T1 (de) 2003-12-23 2009-03-15 Lilly Co Eli Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
EP1793829A1 (de) * 2004-10-01 2007-06-13 Neurocure Ltd. Verwendung von pharmazeutischen zusammensetzungen von lofepramin zur behandlung von adhd, cfs, fm und depression
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
JP2010520885A (ja) 2007-03-09 2010-06-17 チェルシー・セラピューティクス，インコーポレイテッド 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101720186A (zh) * 2007-04-30 2010-06-02 阿得罗公司 (-)-e-10-oh-nt组合物及其合成与使用的方法
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2318362B1 (de) 2008-07-24 2013-09-25 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidinverbindungen
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US7994209B2 (en) 2009-07-13 2011-08-09 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
WO2011011231A1 (en) 2009-07-21 2011-01-27 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CN103153950B (zh) 2010-10-11 2015-11-25 施万生物制药研发Ip有限责任公司 血清素再摄取抑制剂
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
KR20210012056A (ko) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
EP3693020A1 (de) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Kaliumangereicherte topische formulierungen zur schmerzlinderung und schlafhilfe
EP4069244A4 (de) * 2019-12-03 2023-12-20 Axsome Therapeutics, Inc. Verwendung von reboxetin zur behandlung von störungen des nervensystems

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU642582B2 (en) 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0906104A4 (de) 1996-03-25 2003-12-10 Lilly Co Eli Schmerzbehandlungsverfahren
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
EP0856312B1 (de) 1996-11-27 1998-10-14 Dr. R. Pfleger Chemische Fabrik GmbH Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
WO1998046227A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
CA2304112A1 (en) 1997-09-23 1999-04-01 John Harrison Heiligenstein Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
JP2001520195A (ja) * 1997-10-17 2001-10-30 イーライ・リリー・アンド・カンパニー 医薬の増強
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
PT1069900E (pt) * 1998-04-09 2005-10-31 Pharmacia & Upjohn Co Llc Novos tratamentos para disturbios nervosos
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
IL139211A0 (en) 1998-05-08 2001-11-25 Upjohn Co New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
CN1331576A (zh) 1998-06-29 2002-01-16 药品应用协会有限公司 用于缓解疼痛的方法和经皮组合物
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EP2090312A1 (de) * 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) Reboxetine zur Behandlung von Aufmerksamkeitsstörungen
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
NZ520975A (en) * 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
ATE304358T1 (de) 2005-09-15
IL187513A0 (en) 2008-06-05
US20080103147A1 (en) 2008-05-01
WO2001001973A2 (en) 2001-01-11
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
AU771258B2 (en) 2004-03-18
TW200607511A (en) 2006-03-01
ATE305307T1 (de) 2005-10-15
US7338953B2 (en) 2008-03-04
DK1459750T3 (da) 2005-08-15
MXPA02000562A (es) 2002-07-02
DK1632234T3 (da) 2007-09-17
EA200400589A1 (ru) 2004-12-30
ES2247572T3 (es) 2006-03-01
US7723334B2 (en) 2010-05-25
US20020128173A1 (en) 2002-09-12
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
CL2008002866A1 (es) 2009-01-09
DE60026704D1 (de) 2006-05-11
AR035158A1 (es) 2004-05-05
JP2006321815A (ja) 2006-11-30
TW200407146A (en) 2004-05-16
PT1196172E (pt) 2006-05-31
CN1205935C (zh) 2005-06-15
US20060135521A1 (en) 2006-06-22
US20030040464A1 (en) 2003-02-27
CA2643231A1 (en) 2001-01-11
PE20010684A1 (es) 2001-06-24
CN1660110A (zh) 2005-08-31
DE60035232T2 (de) 2008-02-14
ES2258251T3 (es) 2006-08-16
ATE319453T1 (de) 2006-03-15
NZ515885A (en) 2004-08-27
PT1459751E (pt) 2005-11-30
US6642235B2 (en) 2003-11-04
WO2001001973A8 (en) 2001-05-17
KR20050053799A (ko) 2005-06-08
ATE305788T1 (de) 2005-10-15
EA008381B1 (ru) 2007-04-27
DE60020613T2 (de) 2006-03-16
EA200801806A1 (ru) 2008-12-30
DE60022692T2 (de) 2006-06-22
US20060142289A1 (en) 2006-06-29
NZ533243A (en) 2005-12-23
SK286669B6 (sk) 2009-03-05
KR100935277B1 (ko) 2010-01-06
DE60022917T2 (de) 2006-06-29
NO20016406L (no) 2002-02-19
BR0012136A (pt) 2002-06-11
KR20060099544A (ko) 2006-09-19
DE60023043T2 (de) 2006-06-14
KR20020015363A (ko) 2002-02-27
AU5633700A (en) 2001-01-22
US20040147614A1 (en) 2004-07-29
ATE305306T1 (de) 2005-10-15
EA200200111A1 (ru) 2002-06-27
NO20091159L (no) 2002-02-19
SK286104B6 (sk) 2008-03-05
KR20090087135A (ko) 2009-08-14
US7317011B2 (en) 2008-01-08
TW200607509A (en) 2006-03-01
ES2285645T3 (es) 2007-11-16
ES2246487T3 (es) 2006-02-16
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
MY137348A (en) 2009-01-30
ES2246485T3 (es) 2006-02-16
HK1076723A1 (en) 2006-01-27
EA011094B1 (ru) 2008-12-30
US6703389B2 (en) 2004-03-09
US20060128705A1 (en) 2006-06-15
EA200501496A1 (ru) 2006-06-30
DE60022916T2 (de) 2006-07-06
NO20091158L (no) 2002-02-19
SK286864B6 (sk) 2009-06-05
AU2004202096A1 (en) 2004-06-10
US6465458B1 (en) 2002-10-15
DE60026704T2 (de) 2006-10-19
ES2242175T3 (es) 2005-11-01
TW200607510A (en) 2006-03-01
DK1459749T3 (da) 2006-01-09
US20080103145A1 (en) 2008-05-01
US7276503B2 (en) 2007-10-02
PT1459750E (pt) 2005-08-31
KR100717660B1 (ko) 2007-05-15
US6610690B2 (en) 2003-08-26
US20080103146A1 (en) 2008-05-01
AU2004202096B2 (en) 2005-10-20
DE60022692D1 (de) 2005-10-20
HUP0201623A3 (en) 2004-12-28
TWI245631B (en) 2005-12-21
US20060264436A1 (en) 2006-11-23
SK286667B6 (sk) 2009-03-05
SK286668B6 (sk) 2009-03-05
ES2258010T3 (es) 2006-08-16
EP1196172B1 (de) 2006-03-15
EP2090312A1 (de) 2009-08-19
GEP20094798B (en) 2009-10-26
PL196996B1 (pl) 2008-02-29
ES2246488T3 (es) 2006-02-16
TW200914027A (en) 2009-04-01
DE60019473T2 (de) 2006-02-23
ATE296634T1 (de) 2005-06-15
JP2003503450A (ja) 2003-01-28
TWI298255B (en) 2008-07-01
CL2008002868A1 (es) 2009-01-09
US6987107B2 (en) 2006-01-17
CN1660108A (zh) 2005-08-31
TW200607512A (en) 2006-03-01
CZ20014625A3 (cs) 2002-08-14
DE60022916D1 (de) 2006-02-09
US20090247528A1 (en) 2009-10-01
WO2001001973A3 (en) 2002-01-17
CL2008002867A1 (es) 2009-01-09
PL352252A1 (en) 2003-08-11
EA200801805A1 (ru) 2008-12-30
CN1660111A (zh) 2005-08-31
KR20090087134A (ko) 2009-08-14
US20020061910A1 (en) 2002-05-23
NO20016406D0 (no) 2001-12-28
SK19382001A3 (sk) 2002-07-02
US20080096890A1 (en) 2008-04-24
JP2006143749A (ja) 2006-06-08
US20020107249A1 (en) 2002-08-08
CN1660109A (zh) 2005-08-31
KR100704319B1 (ko) 2007-04-09
CZ299847B6 (cs) 2008-12-10
CN1379672A (zh) 2002-11-13
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (de) 2002-04-17
EA005029B1 (ru) 2004-10-28
US7241762B2 (en) 2007-07-10
ATE292971T1 (de) 2005-04-15
DE60022917D1 (de) 2006-02-09
CA2375908C (en) 2006-05-30
KR100948757B1 (ko) 2010-03-23
HK1049630A1 (en) 2003-05-23
ES2239311T3 (es) 2005-09-16
HUP0201623A2 (en) 2002-09-28
NO20091168L (no) 2002-02-19
ATE320257T1 (de) 2006-04-15
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
TWI294779B (en) 2008-03-21
PT1632234E (pt) 2007-07-09
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
TWI293250B (en) 2008-02-11
IL187512A0 (en) 2008-06-05
EP2087892A2 (de) 2009-08-12
TWI298254B (en) 2008-07-01
US20060135520A1 (en) 2006-06-22
DE60035232D1 (de) 2007-07-26
TW200920378A (en) 2009-05-16
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
DE60019473D1 (de) 2005-05-19
CN1289090C (zh) 2006-12-13
EA006652B1 (ru) 2006-02-24
EP2087892A3 (de) 2009-09-30

Similar Documents

Publication Publication Date Title
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60023873D1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE358117T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
TR200200278T2 (tr) Kalsilitik bileşimler
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
EP1261331A4 (de) Methoden und zusammenstellungen zur behandlung von fibrotischen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition